MYCL and prostate adenocarcinoma: Sample types (localized untreated prostate adenocarcinoma [PCa] and/or castration-resistant prostate cancer [CRPC], the number of cases with mutation or copy number alteration (CNA) data, and the number (and %) of cases with SMAD4 mutations and MYCL amplifications are given